Germline Genetic Testing of the TP53 Gene

ConditionsTP53 Gene Mutation Multi-Gene Transcriptional Profiling TP53 Gene Germline Mutation Carrier

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-90

SponsorEuropean Institute of Oncology

About this trial

This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.

Eligibility criteria

Qualifiers

Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO;

Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used;

Have provided written informed consent for participation in scientific research.

Disqualifiers

Absence of signed informed consent for participation in scientific research.

Trial design

Treatments tested in this trial

Not listed

Trial groups

1,940 Participants

are grouped into 3 trial groups

Sponsors and collaborators

European Institute of Oncology

Lead sponsor

Source ClinicalTrials.gov